Speaker Profile
M.D., Director, NUS Academy for Healthy Longevity, National U. of Singapore
Biography
Andrea Maier is a leading figure in geroscience and healthy longevity medicine, academically termed precision geromedicine. Her work has focused on translating the biology of ageing into clinical practice, with emphasis on developing evidence-based strategies to extend healthspan rather than simply prolong lifespan. She has led international cohort studies and intervention studies aimed at understanding ageing mechanisms and applying them to prevention and care.
Maier has shaped precision geromedicine as an organized field. She is the Founding President of the Healthy Longevity Medicine Society, Scientific Advisory Board member of the Biomarkers of Aging Consortium, and she serves on the Board of the Academy for Health and Lifespan Research, roles that place her at the center of efforts to define standards, evidence, and direction for this emerging area.
In addition to her academic leadership, she has worked to build the institutional and clinical infrastructure needed to move precision geromedicine from concept to implementation, including leadership of the Centre for Healthy Longevity at NUS and founding the NUS Academy for Healthy Longevity. Her work has made her one of the most visible international voices connecting ageing biology, clinical medicine, and real-world translational impact.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Michael Goldman, SFSU
PMWC Award Ceremony
• David Sinclair, Harvard
• Steve Horvath, Altos Labs
• Nir Barzilai, Albert Einstein College of Medicine
AI-Driven Biomarkers to Quantify Aging
• Chair: Alex Zhavoronkov, Insilico Medicine
• Mahdi Moqri, Harvard
• Steve Horvath, Altos Labs
• Hussain Ahamed, Ultrahuman
Epigenetic Aging Signatures in Large Human Cohorts
• Varun Dwaraka, TruDiagnostic
AI Systems for Personalized Longevity: How Biomarkers Translate into Actionable Interventions
• Chair: Nathan Price, Buck Institute
• Sherry Zhang, Buck Institute
• Ranjan Sinha, Digbi Health
• Zeenia Framroze, Alethios, Inc.
• John Ramunas, Rejuvenation Technologies
Clinical Trial Design & Functional Endpoints for Healthspan
• Nir Barzilai, Albert Einstein College of Mediciney
The data We Need For AI To Accelerate Longevity Drugs
• Martin Jensen, Gordian Biotechnology
From Genome to an AI-Drive Longevity Platform
• Wei-Wu He, Human Longevity
Wellness Wearables: The Journey to Clinical
• Hussain Ahamed, Ultrahuman
Longevity Medicine: Ambition vs Evidence in the Era of Precision Health
• Aubrey de Grey, LEV Foundation
Precision Aging & Longevity Focused on Limited Lifespan Evidence, Vanishing Blue Zones, and Payer ROI
• S. Jay Olshansky, University of Illinois
Evolutionary perspectives on human lifespan and healthspan
• Michael Gurven, UC Santa Barbara
